Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...